← Leaderboards
Russ Geyer
University Of Washington
$38,219
Attributed
$38,219
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5K · FY2005–07$5K$3.8K$2.5K$1.3K$0
'05
'06
'07
Funding mix
By agency
NIH$38,219 · 10
By mechanism
M01$38,219 · 10
Top collaborators
No co-investigators on record.
Most similar at University Of Washington
Same institution · by research overlap
- Michael H Gelb$24,827,130
- Andre Michael Lieber$20,253,196
- Wesley C Van Voorhis$32,631,211
- Christophe L.m.j. Verlinde$963,803
- Frederick Simmons Buckner$14,937,505
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchPediatric Neoplasm /CancerBrain NeoplasmsClinical Trial Phase IHuman SubjectHuman Therapy EvaluationPatient Oriented ResearchDrug Screening /EvaluationChildrenNeoplasm /Cancer ChemotherapySourceFundingGrantResourcesUnited States National Institutes Of HealthClinical Trials, Phase IRecurrenceInstitutionChildAntineoplasticsComputer Retrieval Of Information On Scientific Projects DatabaseNeoplasm /Cancer PharmacologyResearch PersonnelCentral Nervous System Neoplasms
Grant awards (13)
PBTC-018: A PHASE I TRIAL OF CC-5013 (LENALIDOMIDE)$611
M01 · FY2007 · RR · contact PI
PBTC-022: PHASE II STUDY OF BEVACIZUMAB PLUS IRINOTECAN (CAMPTOSAR)$305
M01 · FY2007 · RR · contact PI
PBTC-020: A PHASE I CLINICAL TRIAL OF AZD2171 IN CHILDREN$305
M01 · FY2007 · RR · contact PI
PBTC-018: A PHASE I TRIAL OF CC-5013 (LENALIDOMIDE$4,962
M01 · FY2006 · RR · contact PI
PBTC-005: PHASE I TRIAL OF TEMOZOLOMIDE AND O6-BENZYLGUANINE IN PEDIATRIC PATIES$1,427
M01 · FY2005 · RR
A PHASE I/II TRIAL OF STI-571 IN CHILDREN WITH POOR PROGNOSIS BRAINSTEM GLIOMAS$1,427
M01 · FY2005 · RR
PBTC-003: ESCALATING ORAL DOSES OF SCH 66336 IN PTS WITH BRAIN TUMORS$712
M01 · FY2005 · RR
PBTC-012: CILENGITIDE (EMD 121974) IN CHILDREN WITH REFRACTORY BRAIN TUMORS$712
M01 · FY2005 · RR
PBTC-005: Phase I Trial of Temozolomide and O6-Benzylguanine in Pediatric Paties$12,144
M01 · FY2004 · RR
A Phase I/II Trial of STI-571 In Children With Poor Prognosis Brainstem Gliomas$6,506
M01 · FY2004 · RR
PBTC-009: Phase I Trial of GLIADEL<and O6-Benzylguanine in Pediatric Patientss$5,205
M01 · FY2004 · RR
Phase I Trial of Escalating Oral Doses of SCH 66336 in Pediatric Patients with s$2,169
M01 · FY2004 · RR
Phase I/II Trial of ZD1839 (IressaO) and Radiation in$1,734
M01 · FY2004 · RR